Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
暂无分享,去创建一个
[1] S. Korsmeyer,et al. Cell Death Critical Control Points , 2004, Cell.
[2] L. Lanier,et al. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] Eric J. Brown,et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.
[4] D. Pardoll,et al. Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.
[5] Mariano J. Alvarez,et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. , 2004, Cancer cell.
[6] E. Jaffee,et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.
[7] Julia M. Lewis,et al. The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin Cancer , 2003, The Journal of experimental medicine.
[8] M. Smyth,et al. Perforin is a major contributor to NK cell control of tumor metastasis. , 1999, Journal of immunology.
[9] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[10] E. Coccia,et al. Molecular mechanisms of action of interferons in the Friend virus-induced leukemia cell system. , 1987, Haematologica.
[11] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[12] F. Belardelli,et al. Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice , 1988, The Journal of experimental medicine.
[13] T. Spies,et al. MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function , 2001 .
[14] M. Colombo,et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.
[15] J. Trapani,et al. Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.
[16] G. Coukos,et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.
[17] S. Sakaguchi. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.
[18] I. Penn. Malignant melanoma in organ allograft recipients. , 1996, Transplantation.
[19] C. Boshoff,et al. Aids-related malignancies , 2002, Nature Reviews Cancer.
[20] S. Lowe,et al. Control of apoptosis by p53 , 2003, Oncogene.
[21] J. Trapani,et al. Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.
[22] J. Trapani,et al. Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.
[23] I. Svane,et al. Methylcholanthrene‐induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[24] L. Old,et al. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Dhodapkar,et al. A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma , 2003, The Journal of experimental medicine.
[26] M. Horton,et al. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. , 1997, Journal of immunology.
[27] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.
[28] S. Lowe,et al. Intrinsic tumour suppression , 2004, Nature.
[29] R. Flavell,et al. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.
[30] M BURNET,et al. Cancer—A Biological Approach* , 1957, British medical journal.
[31] J. Rygaard,et al. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. , 2009, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.
[32] M. Smyth. Type I interferon and cancer immunoediting , 2005, Nature Immunology.
[33] P. Srivastava,et al. Roles of heat-shock proteins in antigen presentation and cross-presentation. , 2002, Current opinion in immunology.
[34] Hideo Negishi,et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence , 2003, Nature.
[35] J. Platt,et al. Receptor-Mediated Monitoring of Tissue Well-Being Via Detection of Soluble Heparan Sulfate by Toll-Like Receptor 41 , 2002, The Journal of Immunology.
[36] S. Sakaguchi. Regulatory T cells , 2000, Cell.
[37] A. Diefenbach,et al. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity , 2003, European journal of immunology.
[38] R. Scheuermann,et al. Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.
[39] J. Tschopp,et al. Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.
[40] D. Carbone,et al. Tumor-host immune interactions and dendritic cell dysfunction. , 2004, Advances in cancer research.
[41] A. Marx,et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. , 2001, Blood.
[42] M. Smyth,et al. NKT cells - conductors of tumor immunity? , 2002, Current opinion in immunology.
[43] R. Ronca,et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.
[44] T. Ahrens,et al. Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4 , 2002, The Journal of experimental medicine.
[45] Zihai Li,et al. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. , 2003, Cancer immunity.
[46] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[47] J. Hess,et al. Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. , 2004, Blood.
[48] M. Smyth,et al. A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas , 2002, The Journal of experimental medicine.
[49] T. Tüting,et al. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.
[50] E. Nakayama,et al. Sequential Involvement of Two Distinct CD4+ Regulatory T Cells during the Course of Transplantable Tumor Growth and Protection from 3–Methylcholanthrene‐induced Tumorigenesis by CD25–depletion , 2002, Japanese journal of cancer research : Gann.
[51] L. Loeb,et al. Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.
[52] D. Longo,et al. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. , 1992, Journal of immunology.
[53] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[54] N. Shastri,et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages , 2000, Nature Immunology.
[55] M. Smyth,et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.
[56] P. Matzinger. Tolerance, danger, and the extended family. , 1994, Annual review of immunology.
[57] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[58] Hiroshi Sato,et al. Requirement for Vα14 NKT Cells in IL-12-Mediated Rejection of Tumors , 1997 .
[59] P. Szlosarek,et al. Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .
[60] M. V. D. van den Brink,et al. Nature's TRAIL--on a path to cancer immunotherapy. , 2003, Immunity.
[61] N. Malats,et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] P. Leder,et al. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.
[63] L. Old,et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes , 2004, Immunogenetics.
[64] Polly Matzinger,et al. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.
[65] Suzanne Cory,et al. The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.
[66] S. Ferrone,et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. , 2002, Cancer research.
[67] R. Darnell. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[68] R. Darnell,et al. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. , 2001, Annual review of neuroscience.
[69] Z. Werb,et al. How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.
[70] P. Medawar. The behaviour and fate of skin autografts and skin homografts in rabbits: A report to the War Wounds Committee of the Medical Research Council. , 1944, Journal of anatomy.
[71] Old Lj,et al. Immunology of Experimental Tumors , 1964 .
[72] E. Unanue,et al. Natural Immunity: A T‐Cell‐Independent Pathway of Macrophage Activation, Defined in the scid Mouse , 1991, Immunological reviews.
[73] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[74] C. Sutherland,et al. ULBP4 is a novel ligand for human NKG2D. , 2003, Biochemical and biophysical research communications.
[75] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[76] Michael J. Wilson,et al. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. , 2002, Genomics.
[77] M. Smyth,et al. Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.
[78] F. Burnet. The concept of immunological surveillance. , 1970, Progress in experimental tumor research.
[79] N. Fausto,et al. Impaired Preneoplastic Changes and Liver Tumor Formation in Tumor Necrosis Factor Receptor Type 1 Knockout Mice , 2000, The Journal of experimental medicine.
[80] R. Flavell,et al. Transforming growth factor-β in T-cell biology , 2002, Nature Reviews Immunology.
[81] R. Darnell,et al. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies , 1993, The Lancet.
[82] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[83] L. Sherman,et al. The composition of the T cell receptor repertoire in nude mice. , 1987, Journal of immunology.
[84] M. Smyth,et al. Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.
[85] M Aguet,et al. The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.
[86] M. Smyth,et al. Alpha-galactosylceramide: potential immunomodulatory activity and future application. , 2004, Current medicinal chemistry.
[87] G. Forni,et al. α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[88] A Steinle,et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.
[89] L. Thomas. THE YALE JOURNAL OF BIOLOGY AND MEDICINE 55 (1982), 329-333 On Immunosurveillance in Human Cancer , 1982 .
[90] S. Natsugoe,et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.
[91] D. Carbone,et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[92] M. Smyth,et al. Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.
[93] Julia M. Lewis,et al. Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.
[94] J. Daly,et al. Long-term spontaneous tumor incidence in neonatally thymectomized mice. , 1973, Journal of immunology.
[95] K. Weinhold,et al. The tumor dormant state. , 1981, Advances in cancer research.
[96] V. Stewart,et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.
[97] M. Smyth,et al. NKT cells: facts, functions and fallacies. , 2000, Immunology today.
[98] O. Tsitsilonis,et al. Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice , 2000, European journal of immunology.
[99] Lin Zhang,et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A , 2004, Nature Medicine.
[100] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[101] E. Lenkiewicz,et al. Defining a Link with Asthma in Mice Congenitally Deficient in Eosinophils , 2004, Science.
[102] G. Trinchieri,et al. Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells , 2002, The Journal of experimental medicine.
[103] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[104] Piero Musiani,et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. , 2003, The Journal of clinical investigation.
[105] R. Flavell,et al. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis , 1997, Molecular and cellular biology.
[106] Wancai Yang,et al. γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity , 2003, The Journal of experimental medicine.
[107] Peter Greenwald,et al. The antioxidant conundrum in cancer. , 2003, Cancer research.
[108] S. Bahram,et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[109] H. Kaplan. Role of Immunologic Disturbance in Human Oncogenesis: Some Facts and Fancies , 1971, British Journal of Cancer.
[110] D. Margulies,et al. MHC class I recognition by Ly49 natural killer cell receptors. , 2002, Molecular immunology.
[111] M. Marino,et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. , 1999, Cancer research.
[112] T. Sayers,et al. NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer , 2004, The Journal of experimental medicine.
[113] Xin-Yuan Fu,et al. Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.
[114] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[115] Y. Shinkai,et al. Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo , 1990, The Journal of experimental medicine.
[116] Yi Luo,et al. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand , 2004, Cancer Research.
[117] K. Macleod. Tumor suppressor genes. , 2000, Current opinion in genetics & development.
[118] R. MacKie,et al. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. , 2003, The New England journal of medicine.
[119] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[120] S. Riddell,et al. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells , 2001, Nature Immunology.
[121] M. A. Sáez,et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.
[122] M. Bevan,et al. Specificity of cytotoxic T cells from athymic mice , 1980, The Journal of experimental medicine.
[123] A. Hayday,et al. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice , 1996, The Journal of experimental medicine.
[124] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[125] N. Hayashi,et al. Critical Role of MHC Class I-Related Chain A and B Expression on IFN-α-Stimulated Dendritic Cells in NK Cell Activation: Impairment in Chronic Hepatitis C Virus Infection 1 , 2003, The Journal of Immunology.
[126] M. Smyth,et al. Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.
[127] T. Giese,et al. Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions , 1998, The Journal of experimental medicine.
[128] R. Schreiber,et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.
[129] R. Schreiber,et al. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. , 2005, Cancer research.
[130] Natale Cascinelli,et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.
[131] Ethan M. Shevach,et al. CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.
[132] T. Noda,et al. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. , 2004, The Journal of clinical investigation.
[133] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[134] F. Garrido,et al. The HLA crossroad in tumor immunology. , 2000, Human immunology.
[135] M. Smyth,et al. An Essential Role for Tumor Necrosis Factor in Natural Killer Cell–mediated Tumor Rejection in the Peritoneum , 1998, The Journal of experimental medicine.
[136] S. Bauer,et al. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. , 1998, Science.
[137] N. Ponzio,et al. B cell lymphomas of C57L/J mice; the role of natural killer cells and T helper cells in lymphoma development and growth. , 2000, Leukemia research.
[138] N. Restifo,et al. Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.
[139] M. Smyth,et al. Cutting Edge: Novel Priming of Tumor-Specific Immunity by NKG2D-Triggered NK Cell-Mediated Tumor Rejection and Th1-Independent CD4+ T Cell Pathway1 , 2004, The Journal of Immunology.
[140] M. Smyth,et al. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.
[141] N. Burstein,et al. Neonatal Thymectomy and Non-viral Mammary Tumours in Mice , 1971, Nature.
[142] B. Ruebner,et al. Anti-mu induces lymphoma in germfree congenitally athymic (nude) but not in heterozygous (nu/+) mice. , 1983, Journal of immunology.
[143] P. Foster,et al. Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.
[144] R. Zinkernagel,et al. Perforin dependence of natural killer cell‐mediated tumor control in vivo , 1995, European journal of immunology.
[145] G. Klein. Immunological surveillance against neoplasia. , 1973, Harvey lectures.
[146] P. Hersey,et al. Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3γ* , 1997, The Journal of Biological Chemistry.
[147] J. Blay,et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.
[148] M. Smyth,et al. Cutting Edge: Tumor Rejection Mediated by NKG2D Receptor-Ligand Interaction Is Dependent upon Perforin1 , 2002, The Journal of Immunology.
[149] F. Alt,et al. Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer , 2003, The Journal of experimental medicine.
[150] H. Richardson,et al. Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.
[151] J. Roder,et al. Spontaneous and induced primary oncogenesis in natural killer (nk)‐cell‐deficient beige mutant mice , 1985, International journal of cancer.
[152] D. Green,et al. The Pathophysiology of Mitochondrial Cell Death , 2004, Science.
[153] S. Johnson. Effect of thymectomy on the induction of skin tumours by dibenzanthracene, and of breast tumours by dimethylbenzanthracene, in mice of the IF strain. , 1968, British Journal of Cancer.
[154] S. Akira,et al. Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice , 2004, Cancer Research.
[155] K. Loeb,et al. Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[156] T. Spies,et al. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB , 1999 .
[157] A. Toubert,et al. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[158] C. Yee,et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.
[159] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[160] M. Colonna,et al. A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. , 2004, Blood.
[161] A. Houghton,et al. Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.
[162] R. Armitage,et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. , 2001, Immunity.
[163] M. Pfreundschuh,et al. Cell surface antigens of human renal cancer defined by autologous typing , 1979, The Journal of experimental medicine.
[164] L. Old. Cancer vaccines 2003: opening address. , 2003, Cancer immunity.
[165] S. Ikehara,et al. Functional T cells in athymic nude mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[166] F. Belardelli,et al. Endogenous type I interferons as a defense against tumors. , 2002, Cytokine & growth factor reviews.
[167] J. Darnell,et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[168] L. Old,et al. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[169] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[170] P. Hogan,et al. Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. , 1998, Transplantation.
[171] Hua Yu,et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.
[172] D. Katz,et al. Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. , 1983, Journal of immunology.
[173] W. Coley. The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .
[174] R. Darnell,et al. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration , 2000, Annals of neurology.
[175] J. Kirkwood,et al. Interferon-alpha in tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.
[176] Yao-Tseng Chen,et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[177] J. Becker,et al. Expression of stress-induced MHC class I related chain molecules on human melanoma. , 2002, The Journal of investigative dermatology.
[178] D. Fremont,et al. Cutting Edge: Murine UL16-Binding Protein-Like Transcript 1: A Newly Described Transcript Encoding a High-Affinity Ligand for Murine NKG2D1 , 2002, The Journal of Immunology.
[179] T. Starzl,et al. Malignant lymphomas in transplantation patients: a review of the world experience. , 1970, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology.
[180] H. Rammensee,et al. Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.
[181] S. Rosenberg,et al. Human tumor antigens for cancer vaccine development , 1999, Immunological reviews.
[182] J. Trapani,et al. Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection , 2003, The Journal of Immunology.
[183] H. Ljunggren,et al. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice , 1996, European journal of immunology.
[184] J. Rygaard,et al. Is immunological surveillance not a cell-mediated immune function? , 1974, Transplantation.
[185] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[186] W. Hahn,et al. Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.
[187] L. Lanier,et al. Ligands for natural killer cell receptors: redundancy or specificity , 2001, Immunological reviews.
[188] L. Old. Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. , 1981, Cancer research.
[189] Jay A. Berzofsky,et al. NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.
[190] A. Diefenbach,et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.
[191] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[192] M. Colonna,et al. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation , 2002, Nature Immunology.
[193] Yao-Tseng Chen,et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.
[194] A. Hayday,et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance , 2005, Nature Immunology.
[195] O. Stutman. Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice , 1974, Science.
[196] A. Winoto,et al. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice , 2005, Cell Death and Differentiation.
[197] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[198] R. Zinkernagel,et al. Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.
[199] C. Mackay,et al. The role of chemokine receptors in primary, effector, and memory immune responses. , 2000, Annual review of immunology.
[200] James E. Evans,et al. Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.
[201] M. Peter,et al. The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.
[202] T. Schumacher,et al. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.
[203] L. O'Hanlon. Natural born killers: NK cells drafted into the cancer fight. , 2004, Journal of the National Cancer Institute.
[204] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[205] J. Trapani,et al. A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.
[206] M. Mihm,et al. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[207] Jeffrey M. Vinocur,et al. LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells , 2003, Cancer biology & therapy.
[208] Mark J. Smyth,et al. Functional significance of the perforin/granzyme cell death pathway , 2002, Nature Reviews Immunology.
[209] A. Balmain,et al. Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell Carcinoma , 2004 .
[210] K. Nomoto,et al. Immunologic properties of methylcholanthrene-induced sarcomas of neonatally thymectomized mice. , 1969, Journal of the National Cancer Institute.
[211] C. D. Krause,et al. Interferons, interferon‐like cytokines, and their receptors , 2004, Immunological reviews.
[212] P. Schlag,et al. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.
[213] P K Lala,et al. Role of nitric oxide in carcinogenesis and tumour progression. , 2001, The Lancet. Oncology.
[214] M. Smyth. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.
[215] C. Caux,et al. Chemokines in cancer. , 2002, Cytokine & growth factor reviews.
[216] Matthew L. Albert,et al. Paraneoplastic neurological degenerations: keys to tumour immunity , 2004, Nature Reviews Cancer.
[217] T. Blankenstein,et al. CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.
[218] O. Stutman. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. , 1979, Journal of the National Cancer Institute.
[219] P. Musiani,et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. , 2001, Blood.
[220] S. Pestka,et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.
[221] Takayuki Asahara,et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.
[222] S. Sakaguchi. Immunologic Tolerance Maintained by Regulatory T Cells: Implications for Autoimmunity, Tumor Immunity and Transplantation Tolerance , 2002, Vox sanguinis.
[223] Loise M. Francisco,et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.
[224] S. Rosenberg,et al. A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.
[225] O. Stutman. Immunodepression and malignancy. , 1975, Advances in cancer research.
[226] J. Berzofsky,et al. Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance , 2003, The Journal of Experimental Medicine.
[227] G. Willimsky,et al. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.
[228] A. Chong,et al. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. , 1998, Cancer research.
[229] P. Hersey,et al. Remission of transplanted melanoma--clinical course and tumour cell characterisation. , 1997, Clinical transplantation.
[230] M. Burnet. IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS. , 1964, British medical bulletin.
[231] M. Nomura,et al. Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: one of the early inducible clones encodes a novel protein sharing several highly homologous regions with a Drosophila polyhomeotic protein. , 1994, Differentiation; research in biological diversity.
[232] Y. Shinkai,et al. Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells , 1990, The Journal of experimental medicine.
[233] R. Darnell,et al. Observing the invisible: successful tumor immunity in humans , 2003, Nature Immunology.
[234] M. Smyth,et al. Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies1 , 2005, The Journal of Immunology.
[235] D. Raulet. Roles of the NKG2D immunoreceptor and its ligands , 2003, Nature Reviews Immunology.
[236] A. M. Hicks,et al. Spontaneous regression of advanced cancer: Identification of a unique genetically determined, age-dependent trait in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[237] D. Pellicci,et al. The Elusive NKT Cell Antigen--Is the Search Over? , 2004, Science.
[238] B. Seliger,et al. Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.
[239] R. Locksley,et al. The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.
[240] C. Nathan,et al. Nitric oxide and macrophage function. , 1997, Annual review of immunology.
[241] J. Crawford,et al. T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.
[242] Aseem Kumar,et al. Defective TNF-α-Induced Apoptosis in STAT1-Null Cells Due to Low Constitutive Levels of Caspases , 1997 .
[243] M. Pfreundschuh,et al. Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[244] S. Lowe,et al. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.
[245] I. Krantz,et al. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.
[246] H. Mellstedt,et al. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A , 2003, International journal of cancer.
[247] H. Ikeda,et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[248] J. Miller,et al. Effect of Neonatal Thymectomy on the Induction of Sarcomata in C57BL Mice , 1965, Nature.
[249] R. Schreiber,et al. A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.
[250] T. Ganz,et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. , 1998, Science.
[251] N. Hayashi,et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid , 2003, International journal of cancer.
[252] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[253] F. Burnet. Immunological Surveillance in Neoplasia , 1971, Transplantation reviews.
[254] Petr Pancoska,et al. p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.
[255] R. Schreiber,et al. Response to 'A cancer immunosurveillance controversy' , 2004, Nature Immunology.
[256] G. Kollias,et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.
[257] P. Srivastava,et al. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. , 2002, Annual review of immunology.
[258] S. Coca,et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.
[259] C. Janeway. Approaching the asymptote? Evolution and revolution in immunology. , 1989, Cold Spring Harbor symposia on quantitative biology.
[260] M. Smyth,et al. NKT cells and tumor immunity—a double-edged sword , 2000, Nature Immunology.
[261] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[262] R. Proia,et al. Lysosomal Glycosphingolipid Recognition by NKT Cells , 2004, Science.
[263] T. Eberlein,et al. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.
[264] M. Smyth,et al. NKG2D function protects the host from tumor initiation , 2005, The Journal of experimental medicine.
[265] D. Gabrilovich. Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.
[266] G. Wong,et al. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor , 1989, Cell.
[267] E. Proietti,et al. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors , 1983, The Journal of experimental medicine.
[268] R. Custer,et al. Spontaneous and induced tumor incidence in germfree "nude" mice. , 1975, Journal of the Reticuloendothelial Society.
[269] Takuma Hayashi,et al. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. , 2002, Cancer research.
[270] H. Schreiber,et al. Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.